GenSight Biologics Company

We are an innovative clinical-stage gene therapy company currently focused on discovering, developing and commercializing novel therapies for patients with severe retinal neurodegenerative diseases. In the longer term, we hope to find solutions for patients faced with neurodegenerative diseases more generally.

Funding Status: IPO
Estimated Revenue: $1M to $10M
Technology: Neurological Disorders
Founded Date: 2012
Headquarters: France
Industry: Energetic Process